Utility of contrast-enhanced MRI radiomics features combined with clinical indicators for predicting induction chemotherapy response in primary central nervous system lymphoma
ConclusionsOur prediction model, which combines radiomics signatures from CE-MRI with serum IL-2R, can effectively stratify patients with PCNSL before high-dose methotrexate (HD-MTX) -based chemotherapy. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - February 3, 2024 Category: Cancer & Oncology Source Type: research
Long-Term Outcomes of Autologous Stem Cell Transplant with Thiotepa, Busulfan, and Cyclophosphamide Conditioning for Patients with Central Nervous System Lymphoma
Central nervous system lymphoma (CNSL) is associated with dismal outcomes and short survival. Treatment of CNSL involves high-dose chemotherapy followed by consolidative autologous stem cell transplant (ASCT). Thiotepa, busulfan and cyclophosphamide (TBC) conditioning improves progression-free survival in CNSL, but further data is needed to evaluate long-term toxicity and survival outcomes. We hereby report our experience in patients with primary and secondary CNSL who received TBC conditioning for ASCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Aseel Alsouqi, Zhexi Lu, Ziyu Huang, Frank Lieberman, Megan Mantica, Jan Drappatz, Rafic Farah Tags: 207 Source Type: research
Primary breast diffuse large B-cell lymphoma characterized by CNS relapse and successful hematopoietic stem cell transplantation salvage therapy
CONCLUSION: Patients with low-risk mIPI scores, CR after first-line treatment, and those who underwent HSCT after the first relapse had significantly better survival. Intrathecal chemotherapy conferred no benefit in preventing CNS relapse. Further research is needed to assess frontline HSCT's effectiveness in improving outcomes and preventing CNS relapses in PB-DLBCL patients.PMID:38296697 | DOI:10.1016/j.jfma.2024.01.020 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - January 31, 2024 Category: General Medicine Authors: Chu-Yi Chan Che-Wei Ou Hung Chang Ming-Chung Kuo Tung-Liang Lin Yu-Shin Hung Jin-Hou Wu Lee-Yung Shih Hsiao-Wen Kao Source Type: research
Case report: Successful treatment of a patient with relapsed/refractory primary central nervous system lymphoma with thiotepa-based induction, autologous stem cell transplantation and maintenance
Despite significant improvements in prognosis, a subset of patients with primary central nervous system lymphoma (PCNSL) remains at high risk for relapse. The treatment of relapsed and refractory (R/R) PCNSL remains a major clinical challenge. Herein, we present a 24-year-old patient with PCNSL who relapsed 4 years after initial diagnosis and subsequently became refractory to high-dose methotrexate (HD-MTX), temozolomide, whole brain radiation therapy (WBRT), ibrutinib, and lenalidomide. She received thiotepa with anti-programmed cell death protein 1 (PD-1) antibody and achieved partial remission and then underwent autolog...
Source: Frontiers in Oncology - January 29, 2024 Category: Cancer & Oncology Source Type: research
Primary central nervous system post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation: a case report
ConclusionsOur case illustrates an unusual presentation of post-transplant lymphoproliferative disorder in the cerebellopontine angle in a patient with a remote history of allogeneic stem cell transplantation. It demonstrates the importance of keeping primary central nervous system post-transplant lymphoproliferative disorder on the differential for patients who present with back pain or headache that have a history of allogeneic stem cell transplant. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - January 19, 2024 Category: Cancer & Oncology Source Type: research
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations —Going beyond the body‐size effect
This study approach may be applicable to the optimization of pediatric dosing of other mAbs and possibly other biologics. (Source: CPT: Pharmacometrics and Systems Pharmacology)
Source: CPT: Pharmacometrics and Systems Pharmacology - January 8, 2024 Category: Drugs & Pharmacology Authors: Zheyi Hu,
Sihang Liu,
Yue Zhao,
Shengnan Du,
Lora Hamuro,
Jun Shen,
Amit Roy,
Li Zhu Tags: ARTICLE Source Type: research
Comparative evaluation of 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography for distinguishing between primary central nervous system lymphoma and isocitrate dehydrogenase-wildtype glioblastoma
ConclusionMET PET could detect both PCNSL and IDH-wildtype glioblastoma, but unlike FDG PET, it could not distinguish between these two major malignant brain tumors. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - December 31, 2023 Category: Cancer & Oncology Source Type: research
Primary central nervous system lymphoma in the right lateral ventricle and the fourth ventricle: A case report
Asian J Surg. 2023 Dec 29:S1015-9584(23)02013-4. doi: 10.1016/j.asjsur.2023.12.048. Online ahead of print.NO ABSTRACTPMID:38160138 | DOI:10.1016/j.asjsur.2023.12.048 (Source: Asian Journal of Surgery)
Source: Asian Journal of Surgery - December 30, 2023 Category: Surgery Authors: Yu-Xian Wu Li Guo Hao Guo Source Type: research
The Impact of Time From Diagnosis to Initiation of Chemotherapy on Survival of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration
CONCLUSION: Our study shows that a TDT equal to or less than 1 week is associated with adverse clinical factors, worse outcomes, and response in DLBCL, even after adjusting for multiple known poor prognostic factors. This was the first time that response to first-line therapy was correlated to time to treatment. Our findings support ongoing efforts to improve currently standardized prognostic tools and the incorporation of TDT into clinical trials to avoid selection bias.PMID:38151390 | DOI:10.1016/j.clml.2023.11.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Gabriel Roman Souza Zohra Nooruddin Sophia Lee Lauren Boyle Kana Tai Lucero Snegha Ananth Kathleen Franklin Michael Mader Esteban Toro Velez Amna Naqvi Supreet Kaur Source Type: research
The Impact of Time From Diagnosis to Initiation of Chemotherapy on Survival of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration
CONCLUSION: Our study shows that a TDT equal to or less than 1 week is associated with adverse clinical factors, worse outcomes, and response in DLBCL, even after adjusting for multiple known poor prognostic factors. This was the first time that response to first-line therapy was correlated to time to treatment. Our findings support ongoing efforts to improve currently standardized prognostic tools and the incorporation of TDT into clinical trials to avoid selection bias.PMID:38151390 | DOI:10.1016/j.clml.2023.11.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Gabriel Roman Souza Zohra Nooruddin Sophia Lee Lauren Boyle Kana Tai Lucero Snegha Ananth Kathleen Franklin Michael Mader Esteban Toro Velez Amna Naqvi Supreet Kaur Source Type: research
The Impact of Time From Diagnosis to Initiation of Chemotherapy on Survival of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration
CONCLUSION: Our study shows that a TDT equal to or less than 1 week is associated with adverse clinical factors, worse outcomes, and response in DLBCL, even after adjusting for multiple known poor prognostic factors. This was the first time that response to first-line therapy was correlated to time to treatment. Our findings support ongoing efforts to improve currently standardized prognostic tools and the incorporation of TDT into clinical trials to avoid selection bias.PMID:38151390 | DOI:10.1016/j.clml.2023.11.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Gabriel Roman Souza Zohra Nooruddin Sophia Lee Lauren Boyle Kana Tai Lucero Snegha Ananth Kathleen Franklin Michael Mader Esteban Toro Velez Amna Naqvi Supreet Kaur Source Type: research
The Impact of Time From Diagnosis to Initiation of Chemotherapy on Survival of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration
CONCLUSION: Our study shows that a TDT equal to or less than 1 week is associated with adverse clinical factors, worse outcomes, and response in DLBCL, even after adjusting for multiple known poor prognostic factors. This was the first time that response to first-line therapy was correlated to time to treatment. Our findings support ongoing efforts to improve currently standardized prognostic tools and the incorporation of TDT into clinical trials to avoid selection bias.PMID:38151390 | DOI:10.1016/j.clml.2023.11.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Gabriel Roman Souza Zohra Nooruddin Sophia Lee Lauren Boyle Kana Tai Lucero Snegha Ananth Kathleen Franklin Michael Mader Esteban Toro Velez Amna Naqvi Supreet Kaur Source Type: research
The Impact of Time From Diagnosis to Initiation of Chemotherapy on Survival of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration
CONCLUSION: Our study shows that a TDT equal to or less than 1 week is associated with adverse clinical factors, worse outcomes, and response in DLBCL, even after adjusting for multiple known poor prognostic factors. This was the first time that response to first-line therapy was correlated to time to treatment. Our findings support ongoing efforts to improve currently standardized prognostic tools and the incorporation of TDT into clinical trials to avoid selection bias.PMID:38151390 | DOI:10.1016/j.clml.2023.11.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Gabriel Roman Souza Zohra Nooruddin Sophia Lee Lauren Boyle Kana Tai Lucero Snegha Ananth Kathleen Franklin Michael Mader Esteban Toro Velez Amna Naqvi Supreet Kaur Source Type: research
The Impact of Time From Diagnosis to Initiation of Chemotherapy on Survival of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration
CONCLUSION: Our study shows that a TDT equal to or less than 1 week is associated with adverse clinical factors, worse outcomes, and response in DLBCL, even after adjusting for multiple known poor prognostic factors. This was the first time that response to first-line therapy was correlated to time to treatment. Our findings support ongoing efforts to improve currently standardized prognostic tools and the incorporation of TDT into clinical trials to avoid selection bias.PMID:38151390 | DOI:10.1016/j.clml.2023.11.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 27, 2023 Category: Cancer & Oncology Authors: Gabriel Roman Souza Zohra Nooruddin Sophia Lee Lauren Boyle Kana Tai Lucero Snegha Ananth Kathleen Franklin Michael Mader Esteban Toro Velez Amna Naqvi Supreet Kaur Source Type: research
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations —going beyond the body‐size effect
This study approach may be applicable to the optimization of pediatric dosing o f other mAbs and possibly other biologics. (Source: CPT: Pharmacometrics and Systems Pharmacology)
Source: CPT: Pharmacometrics and Systems Pharmacology - December 20, 2023 Category: Drugs & Pharmacology Authors: Zheyi Hu,
Sihang Liu,
Yue Zhao,
Shengnan Du,
Lora Hamuro,
Jun Shen,
Amit Roy,
Li Zhu Tags: ARTICLE Source Type: research
